Cover Image

Ipilimumab: Melanoma and beyond

Saved in:

Bibliographic Details
Main Authors:	Vishal Patel (Author), Hardik Gandhi (Author), Aman Upaganlawar (Author)
Format:	Book
Published:	Wolters Kluwer Medknow Publications, 2011-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tesamorelin: A hope for ART-induced lipodystrophy
by: Akash Patel, et al.
Published: (2011)

Use of ipilimumab in the treatment of melanoma
by: Acharya UH, et al.
Published: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
by: Makiko Ban-Hoefen MD, et al.
Published: (2016)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
by: Patel SP, et al.
Published: (2011)

Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
by: Michael P. Chu, et al.
Published: (2020)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
by: Gérald E. Piérard, et al.
Published: (2012)

HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab
by: Andrea Ladányi, et al.
Published: (2022)

Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
by: Yuri Sakaguchi, et al.
Published: (2020)

Panhypopituitarism induced by ipilimumab
by: Miyu Shiratori, et al.
Published: (2020)

A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma
by: Hansoo Kim, et al.
Published: (2018)

Malignant melanoma of inner canthus with long‐term survival after resection of brain metastasis and treatment with ipilimumab
by: Masahito Yasuda, et al.
Published: (2023)

Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body‐size effect
by: Zheyi Hu, et al.
Published: (2024)

Urticaria multiforme following nivolumab-ipilimumab therapy
by: Sonal Muzumdar, et al.
Published: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022)

Linking Tumor Growth Dynamics to Survival in Ipilimumab‐Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling
by: Yan Feng, et al.
Published: (2019)

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes
by: Chen P, et al.
Published: (2018)

CD30+ lymphomatoid skin toxicity secondary to ipilimumab
by: Amelia E. Bush, BS, et al.
Published: (2020)

Pediatric model‐based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma
by: Shengnan Du, et al.
Published: (2024)

Hyponatremia and Fever in a Patient on Ipilimumab and Nivolumab (Immune Checkpoint Inhibitors): A Case Report
by: Sumit S. Patel MD, et al.
Published: (2021)

A case of ruptured Baker's cyst induced by nivolumab and ipilimumab
by: Marie Kubo, et al.
Published: (2023)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
by: Jason Zhang, et al.
Published: (2019)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
by: Kinjal Sanghavi, et al.
Published: (2020)

Beyond PD-1 Immunotherapy in Malignant Melanoma
by: Dominika Kwiatkowska, et al.
Published: (2019)

A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects
by: Akira Utsunomiya, et al.
Published: (2018)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
by: Pramod Savarapu, et al.
Published: (2021)

Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma
by: Andrey Moiseyenko, et al.
Published: (2020)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
by: John A. Storwick, et al.
Published: (2024)

Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage
by: Bushra Khan, et al.
Published: (2024)

Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult
by: Courtney M. Kenyon, BS, et al.
Published: (2024)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019)

Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid
by: Mika M. Tabata, BS, et al.
Published: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
by: Zhuo-miao Ye, et al.
Published: (2022)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
by: Xuezhi Hao, et al.
Published: (2021)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
by: Matthew D. Tucker, et al.
Published: (2021)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
by: Yi Yang, et al.
Published: (2020)

Nephroprotective Effect of Coenzyme Q10 alone and in Combination with N-acetylcysteine in Diabetic Nephropathy
by: Mahajan Manojkumar S., et al.
Published: (2021)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
by: Bruno Sangro, et al.
Published: (2023)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
by: Felipe Ades, et al.
Published: (2012)